Philippe Calais
Chairman at TRANSCODE THERAPEUTICS, INC.
Net worth: 83 $ as of 30/04/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Thomas Fitzgerald | M | 73 | 6 years | |
| Mark S. Wilson | M | - |
MatriSys Bioscience, Inc.
 MatriSys Bioscience, Inc. BiotechnologyHealth Technology MatriSys Bioscience, Inc. engages in the development of biologic therapeutics. It offers therapies for dermatology and skin care conditions including atopic dermatitis, rosacea, psoriasis, acne, and skin infections. The company was founded by Mark S. Wilson and Richard L. Gallo in 2015 and is headquartered in La Jolla, CA. | 9 years |
| Magda Marquet | M | 65 |
MatriSys Bioscience, Inc.
MatriSys Bioscience, Inc. BiotechnologyHealth Technology MatriSys Bioscience, Inc. engages in the development of biologic therapeutics. It offers therapies for dermatology and skin care conditions including atopic dermatitis, rosacea, psoriasis, acne, and skin infections. The company was founded by Mark S. Wilson and Richard L. Gallo in 2015 and is headquartered in La Jolla, CA. | 6 years |
| Zdravka Medarova | M | 50 | 8 years | |
| Andreas Orfanos | M | - | 20 years | |
| Erik Manting | M | 53 | 4 years | |
| James M. Mackay | M | - |
MatriSys Bioscience, Inc.
MatriSys Bioscience, Inc. BiotechnologyHealth Technology MatriSys Bioscience, Inc. engages in the development of biologic therapeutics. It offers therapies for dermatology and skin care conditions including atopic dermatitis, rosacea, psoriasis, acne, and skin infections. The company was founded by Mark S. Wilson and Richard L. Gallo in 2015 and is headquartered in La Jolla, CA. | 4 years |
| Susan Duggan | F | - | - | |
| Jennifer Giottonini Cayer | F | - |
MatriSys Bioscience, Inc.
MatriSys Bioscience, Inc. BiotechnologyHealth Technology MatriSys Bioscience, Inc. engages in the development of biologic therapeutics. It offers therapies for dermatology and skin care conditions including atopic dermatitis, rosacea, psoriasis, acne, and skin infections. The company was founded by Mark S. Wilson and Richard L. Gallo in 2015 and is headquartered in La Jolla, CA. | 5 years |
| Laurent Choppe | M | - |
Neurochem (International) Ltd.
 Neurochem (International) Ltd. Miscellaneous Commercial ServicesCommercial Services Neurochem (International) Ltd. provides licensing and partnering activities. Its services include supply chain management and sales, clinical, and regulatory & marketing functions required to develop products. Neurochem is headquartered in Lausanne, Switzerland. | 20 years |
| Robert Eastlack | M | 51 |
MatriSys Bioscience, Inc.
MatriSys Bioscience, Inc. BiotechnologyHealth Technology MatriSys Bioscience, Inc. engages in the development of biologic therapeutics. It offers therapies for dermatology and skin care conditions including atopic dermatitis, rosacea, psoriasis, acne, and skin infections. The company was founded by Mark S. Wilson and Richard L. Gallo in 2015 and is headquartered in La Jolla, CA. | 6 years |
| Alan Freidman | M | - | - | |
| Seth Gregg | M | - | - | |
| Carey Ng | F | - |
MatriSys Bioscience, Inc.
MatriSys Bioscience, Inc. BiotechnologyHealth Technology MatriSys Bioscience, Inc. engages in the development of biologic therapeutics. It offers therapies for dermatology and skin care conditions including atopic dermatitis, rosacea, psoriasis, acne, and skin infections. The company was founded by Mark S. Wilson and Richard L. Gallo in 2015 and is headquartered in La Jolla, CA. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Richard la Rue | M | - |
Ambrilia Biopharma, Inc.
 Ambrilia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada. | 1 years |
| Philip C. Ranker | M | 64 | 7 years | |
| Robert Dudley | M | 74 | 8 years | |
| François Desjardins | M | 61 | 19 years | |
| Joseph W. Ramelli | M | 55 | 6 years | |
| David Greenwood | M | 72 | 4 years | |
| Timothy Boris | M | 55 | 2 years | |
| Misha Petkevich | M | 75 | 4 years | |
| Isaac Blech | M | 73 | 2 years | |
| David Skinner | M | - | 8 years | |
| Phyllis Gardner | M | 73 | 3 years | |
| Stefan Loren | M | 60 | 5 years | |
| Erik Emerson | M | 53 | 2 years | |
| Amit Bhupendra Shah | M | 57 | 1 years | |
| Steven Engle | M | 69 | 2 years | |
| Neil William Flanzraich | M | 80 | 6 years | |
| Larn Hwang | M | 61 | - | |
| Sunil Antani | M | - |
Neurochem (International) Ltd.
Neurochem (International) Ltd. Miscellaneous Commercial ServicesCommercial Services Neurochem (International) Ltd. provides licensing and partnering activities. Its services include supply chain management and sales, clinical, and regulatory & marketing functions required to develop products. Neurochem is headquartered in Lausanne, Switzerland. | 2 years |
| Judy Carmody | M | 57 | - | |
| Peter D. Weinstein | M | 61 | 1 years | |
| Felicia Amilcar | F | - | 3 years | |
| Dustan Bonnin | M | - | 2 years | |
| Jordyn Tarazi | F | - | 3 years | |
| Tom Vanthienen | M | - |
Neurochem (International) Ltd.
Neurochem (International) Ltd. Miscellaneous Commercial ServicesCommercial Services Neurochem (International) Ltd. provides licensing and partnering activities. Its services include supply chain management and sales, clinical, and regulatory & marketing functions required to develop products. Neurochem is headquartered in Lausanne, Switzerland. | - |
| Mihir Munsif | M | 61 | - | |
| Graeme K. Rutledge | M | 82 | - | |
| Jan Alan Alfheim | M | - | 4 years | |
| Mariano Rodriguez | M | 54 | 4 years | |
| Seymour H. Fein | M | 75 | - | |
| Jinzi Wu | M | 61 |
Ambrilia Biopharma, Inc.
Ambrilia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada. | 4 years |
| Barry D. Greenberg | M | - | - | |
| Monique Létourneau | F | - |
Ambrilia Biopharma, Inc.
Ambrilia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada. | 8 years |
| Simon Allen | M | 56 | 2 years | |
| Calin Rovinescu | M | 68 | 3 years | |
| John Bernbach | M | 80 | - | |
| François M. Legault | M | 67 | - | |
| Jean-Guy Desjardins | M | 79 | - | |
| Alan Dunton | M | 70 | 6 years | |
| Chandrakant Panchal | M | 74 |
Ambrilia Biopharma, Inc.
Ambrilia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada. | 2 years |
| André Roger Desmarais | M | 68 | 3 years | |
| Ronald M. Nordmann | M | 82 | - | |
| Qiyong Liu | M | 60 | 3 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 34 | 60.71% |
| Canada | 19 | 33.93% |
| Switzerland | 3 | 5.36% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Philippe Calais
- Personal Network
